The co-administration of enzalutamide with a therapeutic vaccine targeting the Twist protein in an in vivo prostate cancer model achieved overall survival [46], opening the way for corresponding approaches in breast cancer. This evidence concerns the gene TWIST1 and Familial prostate cancer.